UNSPSC 51272902: Fospropofol

This classification denotes an anesthetic agent with the molecular formula C13H19O5P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LZ257RZP7K, chemically known as methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate but generally known as fospropofol, which bears US NIH Compound Identifier 3038497. European Medicines Agency schedules Fospropofol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32986. Most nations schedule fospropofol under HS 29199000 and SITC 51631.

As of Q4 2014, FOSPROPOFOL remains the US FDA Preferred Term for this commodity. Fospropofol bears US NLM identifiers UMLS ID C2370726 and NCI Concept Code C76954. SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O.

UNSPSC 51272902 Fospropofol is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code show a divergence from fospropofol specifically toward broader pharmaceutical procurement including naloxone, generic pharmaceuticals, and over-the-counter products. State and local governments use this code to source controlled substances, emergency pharmaceuticals, and generic drug inventories through county health departments, state health and human services agencies, and cooperative purchasing alliances. Issuing bodies span county health systems, state pharmacy benefit programs, and multistate cooperative purchasing vehicles; Seminole County, Florida and the Texas Health and Human Services Commission appear as recent procurers, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers shared pharmaceutical procurement across multiple state and local members.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, requiring fixed-fee pricing and E-Verify compliance. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance, with awards effective July 1, 2026.